NEWS

Cancer Research: CHF 1.1 Million for Novochizol SA

EPFL and Novochizol SA to collaborate on designing more efficient immunotherapies, with the support of Innosuisse, the Swiss Innovation Agency. The EPFL Laboratory of Biomaterials for Immunoengineering, headed by Prof. Li Tang, and the BioArk Monthey– hosted startup company Novochizol SA possessing a unique chitosan transformation technology, today announced that Innosuisse will co-fund their collaborative

Cancer Research: CHF 1.1 Million for Novochizol SA Read More »

Scroll to Top